BioInvent and ThromboGenics Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study with TB-402

News   Jul 06, 2009

 
BioInvent and ThromboGenics Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study with TB-402
 
 
 

RELATED ARTICLES

Developing a Gene Therapy for Deaf Patients

News

OSU researchers have taken an important step toward gene therapy for deaf patients by developing a way to better study a large protein essential for hearing and finding a truncated version of it.

READ MORE

Hits for a Novel Drug Target Identified for Depression and Pain

News

Novel small molecules have been identified that might be transformed into a new medical treatment of depression and/or even the potential in the treatment of pain.

READ MORE

CRISPR Reveals the Sugary Secrets of the Cancer-related Notch Protein

News

New research shows that the fucose and glucose modifications serve as quality-control markers that allow Notch to be transported to its final destination in the cell membrane.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE